Eterna (ERNA) Therapeutics announced a successful inaugural meeting of its newly formed Scientific Advisory Board, SAB. The meeting brought together leading experts in cell therapy to evaluate preclinical advances, address key scientific questions, refine the company’s research and development priorities, and discuss the roadmap to human clinical trials. The board consists of leaders in the field, including: Michael Andreeff; Christopher Rohde; Blythe Sather; Jerome B. Zeldis
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ERNA: